Pfizer Inc. and the company’s German partner BioNTech SE on March 15 filed an application with U.S. regulators seeking emergency use authorization for a second booster shot of their COVID-19 vaccine for people aged 65 and older.
Moderna announced that the first participant was dosed in a Phase I trial of the company’s HIV trimer mRNA vaccine, mRNA-1574.
Moderna Inc. plans to develop and begin testing vaccines targeting 15 of the world’s most worrisome pathogens by 2025 and will permanently waive the company’s COVID-19 vaccine patents for shots intended for certain low-income and middle-income countries.
Top U.S. health officials on March 2 laid out a national blueprint to manage COVID-19 going forward, vowing to prepare for any new variant outbreaks without shutting down schools and businesses and calling for additional funding from Congress.
Moderna is facing additional challenges to patent the COVID-19 vaccine Spikevax, as Arbutus Biopharma and Genevant filed a lawsuit against the company challenging patent infringement.
Researchers at the University of Copenhagen – The Faculty of Health and Medical Sciences found that activating a specialized group of neurons within the brainstem of mice restored full movement function in mice with symptoms of Parkinson’s disease.
Top U.S. infectious disease expert Dr. Anthony Fauci said on February 16 that it is time for the United States to start inching back towards normality, despite remaining risks from COVID-19.
Researchers at Bar-Ilan University and the Galilee Medical Center identified an association between vitamin D deficiency and severity and mortality of COVID-19.
Merck & Co. and Ridgeback Biotherapeutics announced they have supplied about 3.1 million courses of their antiviral drug against COVID-19, molnupiravir, to the U.S. government. In other news, a study funded by the National Institutes of Health found that vaccination against COVID-19 not only protects pregnant women against the disease but their babies as well.
Alzheon posted positive results from the company’s Phase II biomarker trial on ALZ-801 (valiltramiprosate) in patients diagnosed with neurodegenerative disorders such as Alzheimer’s disease.
